Director/PDMR Shareholding

RNS Number : 9937Z

Epistem Holdings plc

01 October 2009

 



Epistem Holdings Plc ('Epistem' or the 'Company')

Directors' Shareholdings

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009. 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 330 ordinary shares of 1.5p each. These shares were acquired in tranches at the end of July, August and September at prices of 358p, 325p and 340p respectively.

The current beneficial interests of the executive Directors are set out below:

Matthew Walls                  6,394             (0.09%)

Dr Catherine Booth        980,749          (13.60%)

Dr Ged Brady                       749            (0.01%)

Dr Jeffrey Moore             15,249            (0.21%)    

John Rylands                 190,647             (2.64%)

For further details please contact:

Epistem Plc

Matthew Walls, CEO                                  [phone]

Piper Jaffray Ltd.

Neil Mackison / Rupert Winckler                [phone]

 

END

 

 

RDSBUGDCCGXGGCG